Sysmex (OTCMKTS:SSMXY – Get Free Report) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.
Sysmex Trading Up 2.8%
OTCMKTS:SSMXY opened at $12.12 on Tuesday. Sysmex has a 12-month low of $8.01 and a 12-month high of $13.49. The firm has a market cap of $7.63 billion, a PE ratio of 28.86 and a beta of 1.05. The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12. The stock has a fifty day moving average price of $9.85 and a 200 day moving average price of $9.20.
Sysmex (OTCMKTS:SSMXY – Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.02. The company had revenue of $825.85 million for the quarter, compared to the consensus estimate of $741.67 million. Sysmex had a return on equity of 7.87% and a net margin of 7.62%.Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. Sell-side analysts anticipate that Sysmex will post 0.38 earnings per share for the current fiscal year.
Sysmex Company Profile
Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.
The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.
Further Reading
- Five stocks we like better than Sysmex
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.
